ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas lifted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3,156.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 147,380 shares of the specialty pharmaceutical company’s stock after acquiring an additional 142,854 shares during the period. Teacher Retirement System of Texas owned 0.68% of ANI Pharmaceuticals worth $9,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in ANIP. Aberdeen Group plc boosted its stake in shares of ANI Pharmaceuticals by 76.1% in the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock worth $28,059,000 after acquiring an additional 181,134 shares during the last quarter. Woodline Partners LP acquired a new position in ANI Pharmaceuticals during the first quarter worth $11,144,000. Global Alpha Capital Management Ltd. boosted its stake in ANI Pharmaceuticals by 17.8% during the first quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company’s stock worth $49,248,000 after buying an additional 111,040 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in ANI Pharmaceuticals during the first quarter worth $7,030,000. Finally, AYAL Capital Advisors Ltd acquired a new position in ANI Pharmaceuticals during the first quarter worth $4,467,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $92.23 on Thursday. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The company has a market capitalization of $2.00 billion, a PE ratio of -119.78 and a beta of 0.58. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $99.50. The business’s fifty day moving average price is $93.54 and its 200 day moving average price is $76.47.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, June 8th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. The firm had revenue of $64.48 million during the quarter. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. On average, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Friday, September 19th. The stock was sold at an average price of $98.04, for a total value of $98,040.00. Following the sale, the senior vice president owned 60,186 shares in the company, valued at approximately $5,900,635.44. The trade was a 1.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Matthew J. Leonard sold 2,528 shares of the business’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $90.62, for a total value of $229,087.36. Following the completion of the sale, the director owned 6,864 shares in the company, valued at $622,015.68. This represents a 26.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 413,830 shares of company stock worth $36,505,378. 11.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of recent research reports. Weiss Ratings raised ANI Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, October 24th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Truist Financial lifted their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. Piper Sandler restated an “overweight” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Finally, Guggenheim lifted their target price on ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $99.14.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.